Epigenetics in Cancer: A Hematological Perspective

PLoS Genetics

Volumn 12, Issue 10, 2016, Pages

  Stahl, Maximilian ^a   Kohrman, Nathan ^a   Gore, Steven D ^a   Kim, Tae Kon ^a   Zeidan, Amer M ^a   Prebet, Thomas ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; AZACITIDINE; BELINOSTAT; CPI 0610; CPI 1205; DECITABINE; DENDRITIC CELL VACCINE; DURVALUMAB; E 7438; ENASIDENIB; HISTONE DEACETYLASE INHIBITOR; IPILIMUMAB; LYSIN SPECIFIC DEMETHYLASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NIVOLUMAB; PANOBINOSTAT; PINOMETOSTAT; RETINOIC ACID; ROMIDEPSIN; TEN 010; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE;

ACUTE MYELOBLASTIC LEUKEMIA; ASXL1 ONCOGENE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DNMT3A ONCOGENE; DRUG RESEARCH; EPIGENETICS; EZH2 ONCOGENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; GENOMIC INSTABILITY; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; IDH1 ONCOGENE; IDH2 ONCOGENE; KTM2A ONCOGENE; LEUKEMOGENESIS; MLL1 ONCOGENE; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NPM1 ONCOGENE; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; REVIEW; RNA SPLICING; TET2 ONCOGENE; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR INVASION; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC DISEASE; HIGH THROUGHPUT SEQUENCING; PATHOLOGY;

CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONES; HUMANS;

EID: 84994360827     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006193     Document Type: Review

References (172)

1. Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.01321376230
2. Hanahan D, Weinberg RA, The hallmarks of cancer. Cell. 2000;100(1):57–70. doi: 10.1016/S0092-8674(00)81683-910647931
3. Holliday R, The inheritance of epigenetic defects. Science. 1987;238(4824):163–70. doi: 10.1126/science.33102303310230
4. Esteller M, Epigenetics in cancer. The New England journal of medicine. 2008;358(11):1148–59. doi: 10.1056/NEJMra07206718337604
5. Dawson MA, Kouzarides T, Huntly BJ, Targeting epigenetic readers in cancer. The New England journal of medicine. 2012;367(7):647–57. doi: 10.1056/NEJMra111263522894577
6. Kouzarides T, Chromatin modifications and their function. Cell. 2007;128(4):693–705. doi: 10.1016/j.cell.2007.02.00517320507
7. Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146(6):1016–28.; PubMed Central PMCID: PMC3176443. doi: 10.1016/j.cell.2011.08.00821925322
8. Kim TK, Gore SD, Zeidan AM, Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars in hematology. 2015;52(3):172–83. doi: 10.1053/j.seminhematol.2015.04.00326111464
9. Jaenisch R, Bird A, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature genetics. 2003;33Suppl:245–54. doi: 10.1038/ng108912610534
10. Woods BA, Levine RL, The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev. 2015;263(1):22–35. doi: 10.1111/imr.1224625510269
11. Shih AH, Abdel-Wahab O, Patel JP, Levine RL, The role of mutations in epigenetic regulators in myeloid malignancies. Nature reviews Cancer. 2012;12(9):599–612. doi: 10.1038/nrc334322898539
12. West AC, Johnstone RW, New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation. 2014;124(1):30–9.; PubMed Central PMCID: PMCPMC3871231. doi: 10.1172/JCI6973824382387
13. Volkel P, Dupret B, Le Bourhis X, Angrand PO, Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res. 2015;7(2):175–93.; PubMed Central PMCID: PMCPMC4399085. 25901190
14. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell. 2010;17(3):225–34.; PubMed Central PMCID: PMC2849316. doi: 10.1016/j.ccr.2010.01.02020171147
15. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010;18(6):553–67.; PubMed Central PMCID: PMC4105845. doi: 10.1016/j.ccr.2010.11.01521130701
16. Pellegrini M, Ferrari R, Epigenetic analysis: ChIP-chip and ChIP-seq. Methods in molecular biology. 2012;802:377–87. doi: 10.1007/978-1-61779-400-1_2522130894
17. Capell BC, Berger SL, Genome-wide epigenetics. The Journal of investigative dermatology. 2013;133(6):e9. doi: 10.1038/jid.2013.17323673507
18. Zhang Y, Jeltsch A, The application of next generation sequencing in DNA methylation analysis. Genes (Basel). 2010;1(1):85–101.; PubMed Central PMCID: PMCPMC3960863. doi: 10.3390/genes101008524710012
19. Zentner GE, Henikoff S, Epigenome editing made easy. Nature biotechnology. 2015;33(6):606–7. doi: 10.1038/nbt.324826057978
20. Rusk N, CRISPRs and epigenome editing. Nature methods. 2014;11(1):28. doi: 10.1038/nmeth.277524524135
21. Rando OJ, Chang HY, Genome-wide views of chromatin structure. Annual review of biochemistry. 2009;78:245–71.; PubMed Central PMCID: PMC2811691. doi: 10.1146/annurev.biochem.78.071107.13463919317649
22. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–37. doi: 10.1016/j.cell.2007.05.00917512414
23. Bannister AJ, Kouzarides T, Regulation of chromatin by histone modifications. Cell research. 2011;21(3):381–95.; PubMed Central PMCID: PMC3193420. doi: 10.1038/cr.2011.2221321607
24. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ, How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nature structural & molecular biology. 2007;14(11):1025–40. doi: 10.1038/nsmb133817984965
25. Ruthenburg AJ, Li H, Patel DJ, Allis CD, Multivalent engagement of chromatin modifications by linked binding modules. Nature reviews Molecular cell biology. 2007;8(12):983–94. doi: 10.1038/nrm229818037899
26. Bheda P, Schneider R, Epigenetics reloaded: the single-cell revolution. Trends in cell biology. 2014;24(11):712–23. doi: 10.1016/j.tcb.2014.08.01025283892
27. Feinberg AP, Vogelstein B, Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89–92. doi: 10.1038/301089a06185846
28. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature medicine. 1995;1(7):686–92. doi: 10.1038/nm0795-6867585152
29. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP, Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. American journal of human genetics. 1991;48(5):880–8.; PubMed Central PMCID: PMC1683063. 1673287
30. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer cell. 2006;9(6):435–43. doi: 10.1016/j.ccr.2006.04.02016766263
31. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer research. 2007;67(4):1424–9. doi: 10.1158/0008-5472.CAN-06-421817308079
32. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature genetics. 2005;37(8):853–62. doi: 10.1038/ng159816007088
33. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer research. 2004;64(16):5527–34. doi: 10.1158/0008-5472.CAN-03-406115313885
34. Eden A, Gaudet F, Waghmare A, Jaenisch R, Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300(5618):455. doi: 10.1126/science.108355712702868
35. Karpf AR, Matsui S, Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer research. 2005;65(19):8635–9. doi: 10.1158/0008-5472.CAN-05-196116204030
36. Bestor TH, Transposons reanimated in mice. Cell. 2005;122(3):322–5. doi: 10.1016/j.cell.2005.07.02416096053
37. Feinberg AP, Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer research. 1999;59(7 Suppl):1743s–6s. 10197590
38. Kaneda A, Feinberg AP, Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer research. 2005;65(24):11236–40. doi: 10.1158/0008-5472.CAN-05-295916357124
39. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM, 3rdJaenisch R, Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer cell. 2005;8(4):275–85. doi: 10.1016/j.ccr.2005.09.00716226703
40. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B, Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989;83(2):155–8. doi: 10.1007/BF002867092550354
41. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(21):9700–4.; PubMed Central PMCID: PMCPMC44884. doi: 10.1073/pnas.91.21.97007937876
42. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564–9. doi: 10.1093/jnci/92.7.56410749912
43. Herman JG, Baylin SB, Gene silencing in cancer in association with promoter hypermethylation. The New England journal of medicine. 2003;349(21):2042–54. doi: 10.1056/NEJMra02307514627790
44. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature genetics. 2000;24(2):132–8. doi: 10.1038/7278510655057
45. Esteller M, Corn PG, Baylin SB, Herman JG, A gene hypermethylation profile of human cancer. Cancer research. 2001;61(8):3225–9. 11309270
46. Esteller M, Cancer epigenomics: DNA methylomes and histone-modification maps. Nature reviews Genetics. 2007;8(4):286–98. doi: 10.1038/nrg200517339880
47. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer cell. 2010;17(1):13–27.; PubMed Central PMCID: PMCPMC3008568. doi: 10.1016/j.ccr.2009.11.02020060365
48. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(4):624–33. doi: 10.1200/JCO.2004.06.06014726504
49. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nature genetics. 2001;27(3):263–70. doi: 10.1038/8582011242107
50. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706–14.; PubMed Central PMCID: PMCPMC2077318. doi: 10.1182/blood-2007-02-07348617671232
51. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011;96(3):384–92.; PubMed Central PMCID: PMCPMC3046269. doi: 10.3324/haematol.2010.03133621134981
52. Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 2009;113(12):2795–804.; PubMed Central PMCID: PMCPMC2945920. doi: 10.1182/blood-2008-08-17238719168792
53. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110–4.; PubMed Central PMCID: PMCPMC4831574. doi: 10.1038/nature1649026700815
54. Kang JY, Song SH, Yun J, Jeon MS, Kim HP, Han SW, et al. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression. Oncogene. 2015;34(45):5677–84. doi: 10.1038/onc.2015.1725703332
55. Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016;351(6280):1454–8. doi: 10.1126/science.aad902426940867
56. Timp W, Feinberg AP, Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nature reviews Cancer. 2013;13(7):497–510.; PubMed Central PMCID: PMC4636434. doi: 10.1038/nrc348623760024
57. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341–7.; PubMed Central PMCID: PMCPMC2743214. doi: 10.1215/15228517-2009-02519435942
58. Abdel-Wahab O, Levine RL, Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563–72.; PubMed Central PMCID: PMC3643757. doi: 10.1182/blood-2013-01-45178123640996
59. Conway O'Brien E, Prideaux S, Chevassut T, The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:103175.; PubMed Central PMCID: PMCPMC3980839. doi: 10.1155/2014/10317524778653
60. Shen H, Laird PW, Interplay between the cancer genome and epigenome. Cell. 2013;153(1):38–55.; PubMed Central PMCID: PMCPMC3648790. doi: 10.1016/j.cell.2013.03.00823540689
61. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine. 2010;363(25):2424–33.; PubMed Central PMCID: PMCPMC3201818. doi: 10.1056/NEJMoa100514321067377
62. Thiede C, Mutant DNMT3A: teaming up to transform. Blood. 2012;119(24):5615–7. doi: 10.1182/blood-2012-04-42390522700693
63. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012;366(12):1079–89.; PubMed Central PMCID: PMCPMC3545649. doi: 10.1056/NEJMoa111230422417203
64. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–8.; PubMed Central PMCID: PMCPMC3202965. doi: 10.1038/leu.2011.4421415852
65. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144–7.; PubMed Central PMCID: PMCPMC2710942. doi: 10.1182/blood-2009-03-21003919420352
66. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803–10. doi: 10.1182/blood-2011-02-33974721828143
67. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905–11.; PubMed Central PMCID: PMCPMC4654629. doi: 10.1038/leu.2009.4719262601
68. Xu F, Li X, The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert review of hematology. 2012;5(2):177–85. doi: 10.1586/ehm.12.522475286
69. Lund K, Adams PD, Copland M, EZH2 in normal and malignant hematopoiesis. Leukemia. 2014;28(1):44–9. doi: 10.1038/leu.2013.28824097338
70. Abdel-Wahab O, Dey A, The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia. 2013;27(1):10–5. doi: 10.1038/leu.2012.28823147254
71. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE. 2011;6(12):e28585.; PubMed Central PMCID: PMCPMC3237460. doi: 10.1371/journal.pone.002858522194861
72. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature genetics. 2010;42(2):181–5.; PubMed Central PMCID: PMCPMC2850970. doi: 10.1038/ng.51820081860
73. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–12. doi: 10.1038/nature1160623051747
74. Aravind L, Iyer LM, The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell cycle. 2012;11(1):119–31.; PubMed Central PMCID: PMCPMC3272235. doi: 10.4161/cc.11.1.1847522186017
75. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012;22(2):180–93.; PubMed Central PMCID: PMCPMC3422511. doi: 10.1016/j.ccr.2012.06.03222897849
76. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of experimental medicine. 2010;207(2):339–44.; PubMed Central PMCID: PMCPMC2822606. doi: 10.1084/jem.2009250620142433
77. Stein EM, IDH2 inhibition in AML: Finally progress?Best practice & research Clinical haematology. 2015;28(2–3):112–5. doi: 10.1016/j.beha.2015.10.01626590767
78. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009;360(8):765–73.; PubMed Central PMCID: PMC2820383. doi: 10.1056/NEJMoa080871019228619
79. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409–12. doi: 10.1182/blood-2010-12-32247921596855
80. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622–6. doi: 10.1126/science.123476923558173
81. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell. 2011;19(1):17–30.; PubMed Central PMCID: PMC3229304. doi: 10.1016/j.ccr.2010.12.01421251613
82. Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(12):1350–7. doi: 10.1200/JCO.2011.39.288622430270
83. Falkenberg KJ, Johnstone RW, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature reviews Drug discovery. 2014;13(9):673–91. doi: 10.1038/nrd436025131830
84. Hug BA, Lazar MA, ETO interacting proteins. Oncogene. 2004;23(24):4270–4. doi: 10.1038/sj.onc.120767415156183
85. Rice KL, de The H, The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. Journal of internal medicine. 2014;276(1):61–70. doi: 10.1111/joim.1220824635409
86. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2011;117(1):234–41.; PubMed Central PMCID: PMCPMC3037746. doi: 10.1182/blood-2010-04-28133720855866
87. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506. Epub 2011/07/01.; PubMed Central PMCID: PMC3159042. doi: 10.1056/NEJMoa101334321714648
88. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920–9.; PubMed Central PMCID: PMCPMC3245212. doi: 10.1182/blood-2011-08-36822522031865
89. Levis M, Targeting IDH: the next big thing in AML. Blood. 2013;122(16):2770–1. doi: 10.1182/blood-2013-09-52244124136078
90. Krivtsov AV, Armstrong SA, MLL translocations, histone modifications and leukaemia stem-cell development. Nature reviews Cancer. 2007;7(11):823–33. doi: 10.1038/nrc225317957188
91. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, et al. The MLL recombinome of acute leukemias. Leukemia. 2006;20(5):777–84. doi: 10.1038/sj.leu.240415016511515
92. Mohan M, Lin C, Guest E, Shilatifard A, Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nature reviews Cancer. 2010;10(10):721–8. doi: 10.1038/nrc291520844554
93. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK, Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 2009;7(11):e1000249.; PubMed Central PMCID: PMC2774266. doi: 10.1371/journal.pbio.100024919956800
94. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Molecular cell. 2010;37(3):429–37.; PubMed Central PMCID: PMC2872029. doi: 10.1016/j.molcel.2010.01.02620159561
95. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML, A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer cell. 2010;17(2):198–212.; PubMed Central PMCID: PMC2824033. doi: 10.1016/j.ccr.2009.12.04020153263
96. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33.; PubMed Central PMCID: PMC3679520. doi: 10.1038/nature1050921964340
97. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–73.; PubMed Central PMCID: PMC3010259. doi: 10.1038/nature0950420871596
98. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524–8.; PubMed Central PMCID: PMC3328300. doi: 10.1038/nature1033421814200
99. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer cell. 2008;14(5):355–68.; PubMed Central PMCID: PMC2591932. doi: 10.1016/j.ccr.2008.10.00118977325
100. Chen CW, Armstrong SA, Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Experimental hematology. 2015;43(8):673–84.; PubMed Central PMCID: PMC4540610. doi: 10.1016/j.exphem.2015.05.01226118503
101. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer cell. 2011;20(1):66–78.; PubMed Central PMCID: PMC3329803. doi: 10.1016/j.ccr.2011.06.01021741597
102. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL, Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer research. 2005;65(24):11367–74. doi: 10.1158/0008-5472.CAN-05-104116357144
103. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003;102(1):262–8. doi: 10.1182/blood-2002-10-322112637319
104. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer cell. 2011;20(1):53–65.; PubMed Central PMCID: PMC4046888. doi: 10.1016/j.ccr.2011.06.00921741596
105. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017–25.; PubMed Central PMCID: PMC3739029. doi: 10.1182/blood-2013-04-49764423801631
106. Chen SJ, Shen Y, Chen Z, A panoramic view of acute myeloid leukemia. Nature genetics. 2013;45(6):586–7. doi: 10.1038/ng.265123715324
107. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nature genetics. 2009;41(12):1350–3.; PubMed Central PMCID: PMC2958040. doi: 10.1038/ng.47119881528
108. Timp W, Levchenko A, Feinberg AP, A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell cycle. 2009;8(3):383–90. doi: 10.4161/cc.8.3.754219177016
109. Fuks F, Milner J, Kouzarides T, BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17(19):2531–4. doi: 10.1038/sj.onc.12024759824164
110. Esteve PO, Chin HG, Pradhan S, Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(4):1000–5.; PubMed Central PMCID: PMC544618. doi: 10.1073/pnas.040772910215657147
111. Campbell PM, Szyf M, Human DNA methyltransferase gene DNMT1 is regulated by the APC pathway. Carcinogenesis. 2003;24(1):17–24. doi: 10.1093/carcin/24.1.1712538344
112. Coomber BL, Yu JL, Fathers KE, Plumb C, Rak JW, Angiogenesis and the role of epigenetics in metastasis. Clinical & experimental metastasis. 2003;20(3):215–27. 12741680
113. Lujambio A, Esteller M, How epigenetics can explain human metastasis: a new role for microRNAs. Cell cycle. 2009;8(3):377–82. doi: 10.4161/cc.8.3.752619177007
114. Jones PA, Baylin SB, The epigenomics of cancer. Cell. 2007;128(4):683–92.; PubMed Central PMCID: PMC3894624. doi: 10.1016/j.cell.2007.01.02917320506
115. Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, et al. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21(18):4040–7. doi: 10.1158/1078-0432.CCR-14-291426374074
116. Carrer A, Wellen KE, Metabolism and epigenetics: a link cancer cells exploit. Current opinion in biotechnology. 2015;34:23–9. doi: 10.1016/j.copbio.2014.11.01225461508
117. Kaelin WG, Jr.McKnight SL, Influence of metabolism on epigenetics and disease. Cell. 2013;153(1):56–69.; PubMed Central PMCID: PMC3775362. doi: 10.1016/j.cell.2013.03.00423540690
118. Sigalotti L, Fratta E, Coral S, Maio M, Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacology & therapeutics. 2014;142(3):339–50. doi: 10.1016/j.pharmthera.2013.12.01524384533
119. Coral S, Parisi G, Nicolay HJ, Colizzi F, Danielli R, Fratta E, et al. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Cancer immunology, immunotherapy: CII. 2013;62(3):605–14. doi: 10.1007/s00262-012-1365-723138873
120. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leukemia research. 2014;38(11):1332–41. doi: 10.1016/j.leukres.2014.09.00125260825
121. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, et al. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. Journal of cellular physiology. 2010;223(2):352–8. doi: 10.1002/jcp.2204020127705
122. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007;13(11):3333–8. doi: 10.1158/1078-0432.CCR-06-309117545540
123. Cairns RA, Mak TW, Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer discovery. 2013;3(7):730–41. doi: 10.1158/2159-8290.CD-13-008323796461
124. Cai L, Sutter BM, Li B, Tu BP, Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Molecular cell. 2011;42(4):426–37.; PubMed Central PMCID: PMC3109073. doi: 10.1016/j.molcel.2011.05.00421596309
125. Kaochar S, Tu BP, Gatekeepers of chromatin: Small metabolites elicit big changes in gene expression. Trends in biochemical sciences. 2012;37(11):477–83.; PubMed Central PMCID: PMC3482309. doi: 10.1016/j.tibs.2012.07.00822944281
126. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9. doi: 10.1038/nature1049621909114
127. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T, Epigenetics in alternative pre-mRNA splicing. Cell. 2011;144(1):16–26.; PubMed Central PMCID: PMCPMC3038581. doi: 10.1016/j.cell.2010.11.05621215366
128. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J, Differential chromatin marking of introns and expressed exons by H3K36me3. Nature genetics. 2009;41(3):376–81.; PubMed Central PMCID: PMCPMC2648722. doi: 10.1038/ng.32219182803
129. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T, Regulation of alternative splicing by histone modifications. Science. 2010;327(5968):996–1000.; PubMed Central PMCID: PMCPMC2913848. doi: 10.1126/science.118420820133523
130. Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012;119(14):3211–8. doi: 10.1182/blood-2011-12-40099422343920
131. Leeke B, Marsman J, O'Sullivan JM, Horsfield JA, Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp Hematol Oncol. 2014;3:13.; PubMed Central PMCID: PMCPMC4046106. doi: 10.1186/2162-3619-3-1324904756
132. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nature genetics. 2013;45(10):1232–7. doi: 10.1038/ng.273123955599
133. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, et al. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell stem cell. 2015;17(6):675–88.; PubMed Central PMCID: PMCPMC4671831. doi: 10.1016/j.stem.2015.09.01726607380
134. Mullenders J, Aranda-Orgilles B, Lhoumaud P, Keller M, Pae J, Wang K, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. The Journal of experimental medicine. 2015;212(11):1833–50.; PubMed Central PMCID: PMCPMC4612095. doi: 10.1084/jem.2015132326438359
135. Garcia-Manero G, Fenaux P, Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(5):516–23.; PubMed Central PMCID: PMC3056493. doi: 10.1200/JCO.2010.31.085421220589
136. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9. doi: 10.1182/blood-2006-06-02599916960145
137. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(29):4485–91. doi: 10.1200/JCO.2010.28.906620697094
138. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K, Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–67. doi: 10.1182/blood-2010-05-23154821493798
139. Laubach JP, Moreau P, San-Miguel JF, Richardson PG, Panobinostat for the Treatment of Multiple Myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21(21):4767–73. doi: 10.1158/1078-0432.CCR-15-053026362997
140. O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33(23):2492–9. doi: 10.1200/JCO.2014.59.278226101246
141. Balasubramanian S, Verner E, Buggy JJ, Isoform-specific histone deacetylase inhibitors: the next step?Cancer letters. 2009;280(2):211–21. doi: 10.1016/j.canlet.2009.02.01319289255
142. Yardley D. A., I-K R, Klein P., Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). J Clin Oncol. 2011;29(suppl 27; abstr 268).
143. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature chemical biology. 2012;8(11):890–6. doi: 10.1038/nchembio.108423023262
144. Kaniskan HU, Konze KD, Jin J, Selective inhibitors of protein methyltransferases. Journal of medicinal chemistry. 2015;58(4):1596–629.; PubMed Central PMCID: PMC4345896. doi: 10.1021/jm501234a25406853
145. Rotili D, Mai A, Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes & cancer. 2011;2(6):663–79.; PubMed Central PMCID: PMC3174264. doi: 10.1177/194760191141797621941621
146. Stein Eytan M, Altman Jessica K, Collins Robert, DeAngelo Daniel J, AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies2014.
147. DiNardo C., S EM, Altman J.K., Collins R., DeAngelo D.J., Fathi A.T., et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies. Haematol Eur Hematol Assoc Annu Meet, 100 (s1) (2015), p. 569 [abstr].
148. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer cell. 2014;26(6):896–908.; PubMed Central PMCID: PMC4291116. doi: 10.1016/j.ccell.2014.10.00925464900
149. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–17.; PubMed Central PMCID: PMC3187920. doi: 10.1016/j.cell.2011.08.01721889194
150. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(40):16669–74.; PubMed Central PMCID: PMC3189078. doi: 10.1073/pnas.110819010821949397
151. Yoo CB, Jones PA, Epigenetic therapy of cancer: past, present and future. Nature reviews Drug discovery. 2006;5(1):37–50. doi: 10.1038/nrd193016485345
152. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Investigational new drugs. 2000;18(1):83–91. 10830142
153. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520(7546):239–42.; PubMed Central PMCID: PMC4393352. doi: 10.1038/nature1412225629630
154. Balch C, Nephew KP, Epigenetic targeting therapies to overcome chemotherapy resistance. Advances in experimental medicine and biology. 2013;754:285–311. doi: 10.1007/978-1-4419-9967-2_1422956507
155. Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2007;18(9):1529–38. doi: 10.1093/annonc/mdm20417761710
156. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(29):4603–9. doi: 10.1200/JCO.2007.10.868817925555
157. Kozar K, Kaminski R, Switaj T, Oldak T, Machaj E, Wysocki PJ, et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003;9(8):3124–33. 12912964
158. Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. British journal of cancer. 2011;105(10):1533–41.; PubMed Central PMCID: PMC3242529.doi: 10.1038/bjc.2011.42822015556
159. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE. 2012;7(1):e30815.; PubMed Central PMCID: PMC3267747. doi: 10.1371/journal.pone.003081522303460
160. Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, et al. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology. 2015;4(8):e1019978.; PubMed Central PMCID: PMC4570131. doi: 10.1080/2162402X.2015.101997826405573
161. Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M, Epigenetics meets immune checkpoints. Seminars in oncology. 2015;42(3):506–13. doi: 10.1053/j.seminoncol.2015.02.00325965370
162. Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(10):4141–6.; PubMed Central PMCID: PMC3054015. doi: 10.1073/pnas.101103710821368108
163. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature genetics. 2012;44(1):23–31.; PubMed Central PMCID: PMC3637952. doi: 10.1038/ng.100922138693
164. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488(7413):656–9.; PubMed Central PMCID: PMC4005896. doi: 10.1038/nature1132322763442
165. Silber JR, Bobola MS, Blank A, Chamberlain MC, O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochimica et biophysica acta. 2012;1826(1):71–82.; PubMed Central PMCID: PMC3340514. doi: 10.1016/j.bbcan.2011.12.00422244911
166. Rodriguez-Paredes M, Esteller M, Cancer epigenetics reaches mainstream oncology. Nature medicine. 2011;17(3):330–9. doi: 10.1038/nm.230521386836
167. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–5.; PubMed Central PMCID: PMC3349233. doi: 10.1038/nature1100522460902
168. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.; PubMed Central PMCID: PMC3320027. doi: 10.1038/nature1100322460905
169. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299(5613):1753–5. doi: 10.1126/science.108090212637750
170. Teschendorff AE, Widschwendter M, Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics. 2012;28(11):1487–94. doi: 10.1093/bioinformatics/bts17022492641
171. Sharma P, Allison JP, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. doi: 10.1016/j.cell.2015.03.03025860605
172. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013;24(8):2174–80.; PubMed Central PMCID: PMC4081656. doi: 10.1093/annonc/mdt16123666915